Neumora Therapeutics (NMRA) Operating Expenses (2022 - 2026)

Neumora Therapeutics' Operating Expenses history runs 5 years deep, the most recent figure standing at $52.9 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 25.48% year-over-year to $52.9 million; the TTM figure through Mar 2026 stood at $223.1 million (down 18.68% YoY), while the FY2025 annual figure was $241.2 million, down 8.47% from the prior year.
• Operating Expenses was $52.9 million for Q1 2026 at Neumora Therapeutics, down from $58.5 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $114.0 million in Q4 2023 to a low of $30.6 million in Q3 2022.
• Historically, Operating Expenses has averaged $58.1 million across 5 years, with a median of $57.7 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Operating Expenses jumped 271.13% in 2023, then sank 44.81% in 2024.
• A 5-year view of Operating Expenses shows it stood at $30.7 million in 2022, then surged by 271.13% to $114.0 million in 2023, then tumbled by 44.81% to $62.9 million in 2024, then slipped by 7.06% to $58.5 million in 2025, then declined by 9.6% to $52.9 million in 2026.
• The last three Operating Expenses figures came in at $52.9 million (Q1 2026), $58.5 million (Q4 2025), and $57.7 million (Q3 2025), per Business Quant data.